The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

In recent years, neutrophils have attracted increasing attention because of their cancer-
promoting effects. An elevated neutrophil-to-lymphocyte ratio is considered a prognostic …

Primary tumors actively and specifically prime pre-metastatic niches (PMNs), the future sites
of organotropic metastasis, preparing these distant microenvironments for disseminated …

Neutrophils are the frontline cells in response to microbial infections and are involved in a
range of inflammatory disorders in the body. In recent years, neutrophils have gained …

Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited
therapeutic options and poor prognosis. In recent years, immunotherapies such as immune …

The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

Background Neutrophil extracellular traps (NETs) were originally thought to be formed by
neutrophils to trap invading microorganisms as a defense mechanism. Increasing studies …

Complex interactions between the immune system and tumor cells exist throughout the
initiation and development of cancer. Although the immune system eliminates malignantly …

The prevalence of liver cancer is constantly rising, with increasing incidence and mortality in
Europe and the USA in recent decades. Among the different subtypes of liver cancers …